FDA clears Mounjaro for heart risk, boosting LLY catalyst
Eli Lilly says the FDA cleared Mounjaro for heart risk, providing a fresh catalyst for LLY shares.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.